1-20 of 56 results for subject:"Side effects"
Librarians' tools
- Search time
- 0.257 seconds
- Solr query time
- 0.01 seconds
- Search query
- subject:"Side effects"
- We searched for
- subject_t:"Side effects" OR subject_t:Side-effects OR subject_ses:93013
Type
House
Session
Year
Department
Member
More
Primary member
Answering member
Legislative stage
Legislation
Subject
More
Publisher
I congratulate the hon. Member for Bolton South East (Yasmin Qureshi) on securing this Back-Bench business debate, which is a great example of such debates being used purposefully to pursue a passionate commitment of a Back Bencher. I also congratulate all the hon. Members who have applied for this debate...
I congratulate the hon. Member for Bolton South East (Yasmin Qureshi) on securing this Back-Bench business debate, which is a great example of such debates being used purposefully to pursue a passionate commitment of a Back Bencher. I also congratulate all the hon. Members who have applied for this debate...
(2) how many people were (a) admitted to and (b) treated in hospital as a result of taking licensed drugs in the last five years.
(2) how many people were (a) admitted to and (b) treated in hospital as a result of taking licensed drugs in the last five years.
| Number of reports | |
| 2006 | 4,635 |
| 2007 | 4,485 |
| 2008 | 4,620 |
| 2009 | 4,475 |
| 2010 | 4,541 |
To ask the Secretary of State for Health (1) how many people were (a) admitted to and (b) treated in hospital as a result of taking natural remedies in the last five years;
To ask the Secretary of State for Health (1) how many people were (a) admitted to and (b) treated in hospital as a result of taking natural remedies in the last five years;
| Number of reports | |
| 2006 | 4,635 |
| 2007 | 4,485 |
| 2008 | 4,620 |
| 2009 | 4,475 |
| 2010 | 4,541 |
(2) how many people in each age cohort experienced an adverse drug reaction in (a) England, (b) each region, (c) each strategic health authority and (d) each primary care trust area in each year since 2003; and how many such reactions in each category were fatal;
(2) how many people in each age cohort experienced an adverse drug reaction in (a) England, (b) each region, (c) each strategic health authority and (d) each primary care trust area in each year since 2003; and how many such reactions in each category were fatal;
| Table 1: Number of suspected ADR reports received by the MHRA between 2003 and 2007 inclusive for antipsychotic drugs | |||
|---|---|---|---|
| All antipsychotics | Atypical antipsychotics | Traditional antipsychotics | |
| 2003 | 1,812 | 1,694 | 140 |
| 2004 | 2,060 | 1,963 | 105 |
| 2005 | 2,614 | 2,473 | 160 |
| 2006 | 2,127 | 1,920 | 226 |
| 2007 | 2,327 | 2,172 | 173 |
| Table 2: Numbers of prescriptions showing numbers of antipsychotic prescription items¹ (in thousands from the PCA database) between 2002 and 2006 | |||
|---|---|---|---|
| All antipsychotics | Atypical antipsychotics | Traditional antipsychotics | |
| 2002 | 5,167.0 | 2,471.6 | 2,695.3 |
| 2003 | 5,513.2 | 3,088.7 | 2,424.4 |
| 2004 | 5,687.8 | 3,333.9 | 2,353.8 |
| 2005 | 5,872.9 | 3,597.7 | 2,275.2 |
| 2006 | 6,196.1 | 4,049.1 | 2,147.0 |
| ¹ Prescriptions items—prescriptions are written on a prescription form. Each single item written on the form is counted as a prescription item. |
| Table 3: Number of suspected ADR reports received by the MHRA from all sources in each of the last 5 years broken down by three age groups | |||
|---|---|---|---|
| Age group | |||
| 50-64 | 65-74 | 75+ | |
| 2003 | 3,832 | 2,633 | 2,595 |
| 2004 | 4,242 | 2,904 | 2,503 |
| 2005 | 4,280 | 2,896 | 2,585 |
| 2006 | 4,414 | 2,919 | 2,374 |
| 2007 | 4,692 | 2,693 | 1,998 |
| Table 4: The number of fatal reports that have been received by the MHRA within the specified time periods broken down by three age groups | |||
|---|---|---|---|
| Age group | |||
| 50-64 | 65-74 | 75+ | |
| 2003 | 139 | 117 | 172 |
| 2004 | 180 | 146 | 196 |
| 2005 | 242 | 174 | 186 |
| 2006 | 201 | 191 | 160 |
| 2007 | 220 | 177 | 184 |
To ask the Secretary of State for Health (1) how many adverse drug reaction reports were received through the yellow card reporting system for (a) all anti-psychotic drugs, (b) traditional anti-psychotic drugs and (c) atypical anti-psychotic drugs in each of the last five years; and how many prescriptions there were...
To ask the Secretary of State for Health (1) how many adverse drug reaction reports were received through the yellow card reporting system for (a) all anti-psychotic drugs, (b) traditional anti-psychotic drugs and (c) atypical anti-psychotic drugs in each of the last five years; and how many prescriptions there were...
| Table 1: Number of suspected ADR reports received by the MHRA between 2003 and 2007 inclusive for antipsychotic drugs | |||
|---|---|---|---|
| All antipsychotics | Atypical antipsychotics | Traditional antipsychotics | |
| 2003 | 1,812 | 1,694 | 140 |
| 2004 | 2,060 | 1,963 | 105 |
| 2005 | 2,614 | 2,473 | 160 |
| 2006 | 2,127 | 1,920 | 226 |
| 2007 | 2,327 | 2,172 | 173 |
| Table 2: Numbers of prescriptions showing numbers of antipsychotic prescription items¹ (in thousands from the PCA database) between 2002 and 2006 | |||
|---|---|---|---|
| All antipsychotics | Atypical antipsychotics | Traditional antipsychotics | |
| 2002 | 5,167.0 | 2,471.6 | 2,695.3 |
| 2003 | 5,513.2 | 3,088.7 | 2,424.4 |
| 2004 | 5,687.8 | 3,333.9 | 2,353.8 |
| 2005 | 5,872.9 | 3,597.7 | 2,275.2 |
| 2006 | 6,196.1 | 4,049.1 | 2,147.0 |
| ¹ Prescriptions items—prescriptions are written on a prescription form. Each single item written on the form is counted as a prescription item. |
| Table 3: Number of suspected ADR reports received by the MHRA from all sources in each of the last 5 years broken down by three age groups | |||
|---|---|---|---|
| Age group | |||
| 50-64 | 65-74 | 75+ | |
| 2003 | 3,832 | 2,633 | 2,595 |
| 2004 | 4,242 | 2,904 | 2,503 |
| 2005 | 4,280 | 2,896 | 2,585 |
| 2006 | 4,414 | 2,919 | 2,374 |
| 2007 | 4,692 | 2,693 | 1,998 |
| Table 4: The number of fatal reports that have been received by the MHRA within the specified time periods broken down by three age groups | |||
|---|---|---|---|
| Age group | |||
| 50-64 | 65-74 | 75+ | |
| 2003 | 139 | 117 | 172 |
| 2004 | 180 | 146 | 196 |
| 2005 | 242 | 174 | 186 |
| 2006 | 201 | 191 | 160 |
| 2007 | 220 | 177 | 184 |
(3) how many people aged between (a) 50 and 64-years-old, (b) 65 and 74-years-old and (c) over 75-years-old (i) died and (ii) were injured by adverse drug reactions in each year since 2003.
(3) how many people aged between (a) 50 and 64-years-old, (b) 65 and 74-years-old and (c) over 75-years-old (i) died and (ii) were injured by adverse drug reactions in each year since 2003.
| Table 1: Number of suspected ADR reports received by the MHRA between 2003 and 2007 inclusive for antipsychotic drugs | |||
|---|---|---|---|
| All antipsychotics | Atypical antipsychotics | Traditional antipsychotics | |
| 2003 | 1,812 | 1,694 | 140 |
| 2004 | 2,060 | 1,963 | 105 |
| 2005 | 2,614 | 2,473 | 160 |
| 2006 | 2,127 | 1,920 | 226 |
| 2007 | 2,327 | 2,172 | 173 |
| Table 2: Numbers of prescriptions showing numbers of antipsychotic prescription items¹ (in thousands from the PCA database) between 2002 and 2006 | |||
|---|---|---|---|
| All antipsychotics | Atypical antipsychotics | Traditional antipsychotics | |
| 2002 | 5,167.0 | 2,471.6 | 2,695.3 |
| 2003 | 5,513.2 | 3,088.7 | 2,424.4 |
| 2004 | 5,687.8 | 3,333.9 | 2,353.8 |
| 2005 | 5,872.9 | 3,597.7 | 2,275.2 |
| 2006 | 6,196.1 | 4,049.1 | 2,147.0 |
| ¹ Prescriptions items—prescriptions are written on a prescription form. Each single item written on the form is counted as a prescription item. |
| Table 3: Number of suspected ADR reports received by the MHRA from all sources in each of the last 5 years broken down by three age groups | |||
|---|---|---|---|
| Age group | |||
| 50-64 | 65-74 | 75+ | |
| 2003 | 3,832 | 2,633 | 2,595 |
| 2004 | 4,242 | 2,904 | 2,503 |
| 2005 | 4,280 | 2,896 | 2,585 |
| 2006 | 4,414 | 2,919 | 2,374 |
| 2007 | 4,692 | 2,693 | 1,998 |
| Table 4: The number of fatal reports that have been received by the MHRA within the specified time periods broken down by three age groups | |||
|---|---|---|---|
| Age group | |||
| 50-64 | 65-74 | 75+ | |
| 2003 | 139 | 117 | 172 |
| 2004 | 180 | 146 | 196 |
| 2005 | 242 | 174 | 186 |
| 2006 | 201 | 191 | 160 |
| 2007 | 220 | 177 | 184 |
To ask the Secretary of State for Health (1) how many people in each strategic health authority have been diagnosed with epilepsy since 1997, broken down by age group;
To ask the Secretary of State for Health (1) how many people in each strategic health authority have been diagnosed with epilepsy since 1997, broken down by age group;
(2) how many patients diagnosed with epilepsy since 1994 have been reported as having suffered an adverse reaction after failing to take their anti-epilepsy drugs as prescribed; and what types of adverse reaction these were.
(2) how many patients diagnosed with epilepsy since 1994 have been reported as having suffered an adverse reaction after failing to take their anti-epilepsy drugs as prescribed; and what types of adverse reaction these were.
To ask the Secretary of State for Health pursuant to the answer of 4 July 2005, Official Report, column 201W, on adverse drug reactions (older people), what the equivalent figures were in 1997.
To ask the Secretary of State for Health pursuant to the answer of 4 July 2005, Official Report, column 201W, on adverse drug reactions (older people), what the equivalent figures were in 1997.
To ask the Secretary of State for Health what estimate she has made of the number of bed days lost due to adverse drug reactions in (a) 50 to 64-year-olds, (b) 65 to 74-year-olds and (c) over 75-year-olds in each of the last five years.
To ask the Secretary of State for Health what estimate she has made of the number of bed days lost due to adverse drug reactions in (a) 50 to 64-year-olds, (b) 65 to 74-year-olds and (c) over 75-year-olds in each of the last five years.
To ask the Secretary of State for Health pursuant to the answer of 4 July 2005, Official Report, column 201W, on adverse drug reactions, what the comparable figures for (a) 1997, (b) 2001 and (c) 2003 were.
To ask the Secretary of State for Health pursuant to the answer of 4 July 2005, Official Report, column 201W, on adverse drug reactions, what the comparable figures for (a) 1997, (b) 2001 and (c) 2003 were.
| Age (years) | Number of ADR reports | Number of fatal ADR reports |
| 1997 | ||
| 50–64 | 3,838 | 84 |
| 65–74 | 2,439 | 88 |
| 75 and over | 1,765 | 106 |
| 2001 | ||
| 50–64 | 5,145 | 137 |
| 65–74 | 2,835 | 104 |
| 75 and over | 2,248 | 151 |
| 2003 | ||
| 50–64 | 3,687 | 139 |
| 65–74 | 2,543 | 118 |
| 75 and over | 2,525 | 170 |
To ask the Secretary of State for Health what her most recent estimate is of the number of (a) 50 to 64-year-olds, (b) 65 to 74-year-olds and (c) over 75-year-olds who (i) died and (ii) were injured in a year as a result of adverse drug reactions.
To ask the Secretary of State for Health what her most recent estimate is of the number of (a) 50 to 64-year-olds, (b) 65 to 74-year-olds and (c) over 75-year-olds who (i) died and (ii) were injured in a year as a result of adverse drug reactions.
| Number of reports received via the yellow card scheme | ||
|---|---|---|
| Age (years) | Number of adverse drug reaction reports | Number of fatal adverse drug reaction reports |
| 50–64 | 4,017 | 180 |
| 65–74 | 2,727 | 143 |
| 75+ | 2,390 | 194 |
That this House believes that consumers have a right to expect full and impartial information about the potential risks and side-effects of prescription medication; further believes that this requires a robust regulatory framework to ensure that information is not only publicly available but also acted upon promptly; and, in the light of continuing consumer disquiet about Seroxat and similar concerns about other medicines, calls for an urgent, full, independent and open review of the UK drug regulatory system.
That this House believes that consumers have a right to expect full and impartial information about the potential risks and side-effects of prescription medication; further believes that this requires a robust regulatory framework to ensure that information is not only publicly available but also acted upon promptly; and, in the...
To ask the Secretary of State for Health, how the Home Office and his Department work together in developing public information publicising the risks of developing schizophrenia from cannabis use aimed at (a) early age users, (b) carers, (c) chronic users and (d) professionals.
To ask the Secretary of State for Health, how the Home Office and his Department work together in developing public information publicising the risks of developing schizophrenia from cannabis use aimed at (a) early age users, (b) carers, (c) chronic users and (d) professionals.
That this House calls for increased awareness and understanding of the physical and psychological effects of Polycystic Ovarian Syndrome (PCOS) which affects five to 10 per cent. of women of working age; recognises that there is no 'one-treatment-fits-all' answer to PCOS management; notes with concern the scarce availability of electrolysis and laser treatment on the NHS; and urges the Government to ensure equal recognition is given to hirsutism as for all other symptoms of PCOS.
That this House calls for increased awareness and understanding of the physical and psychological effects of Polycystic Ovarian Syndrome (PCOS) which affects five to 10 per cent. of women of working age; recognises that there is no 'one-treatment-fits-all' answer to PCOS management; notes with concern the scarce availability of electrolysis...
To ask the Secretary of State for Health, if he will estimate the (a) time spent in hospitals and (b) cost involved in treating a person who has experienced an adverse drug reaction. - Inc figures.
To ask the Secretary of State for Health, if he will estimate the (a) time spent in hospitals and (b) cost involved in treating a person who has experienced an adverse drug reaction. - Inc figures.
To ask the Secretary of State for Health, what progress has been made on the initiative in the Trent region to encourage reporting of adverse drug reactions in the use of medicines in the treatment of children.
To ask the Secretary of State for Health, what progress has been made on the initiative in the Trent region to encourage reporting of adverse drug reactions in the use of medicines in the treatment of children.
To ask the Secretary of State for Health, what plans he has to introduce a system of learning from the yellow card system about the correct dosage and prescribing methods for medicines for children.
To ask the Secretary of State for Health, what plans he has to introduce a system of learning from the yellow card system about the correct dosage and prescribing methods for medicines for children.
To ask the Secretary of State for Health, what the timetable is for introducing a revised version of the British National Formulary for children.
To ask the Secretary of State for Health, what the timetable is for introducing a revised version of the British National Formulary for children.
To ask the Secretary of State for Health, for what reasons only a proportion of adverse incident reports are investigated by the Medicines and Healthcare Products Regulatory Agency as stated in its Annual Report and Accounts 2003-04. - Inc ref to Device Bulletin DB2004(1) - Adverse Incident Reports 2003, copy...
To ask the Secretary of State for Health, for what reasons only a proportion of adverse incident reports are investigated by the Medicines and Healthcare Products Regulatory Agency as stated in its Annual Report and Accounts 2003-04. - Inc ref to Device Bulletin DB2004(1) - Adverse Incident Reports 2003, copy...